Status:

ACTIVE_NOT_RECRUITING

PERCEVAL S Valve Clinical Study for Chinese Registration

Lead Sponsor:

Corcym S.r.l

Conditions:

Aortic Valve Disease

Aortic Valve Stenosis

Eligibility:

All Genders

60+ years

Phase:

NA

Brief Summary

This is a prospective, open, single arm, multi-center clinical study in China. The primary objective of this study is to demonstrate the safety and effectiveness of the PERCEVAL S heart valve when use...

Eligibility Criteria

Inclusion

  • Subject of age \> 60 years.
  • Subject with aortic valve stenosis or steno-insufficiency.
  • Subject has signed the informed consent.
  • Subject in which preoperative evaluation is indicated for the need of native or prosthetic aortic valve replacement via open heart surgery
  • Subject is located in a geographic location that will enable the subject to return to the study site for follow-up examinations (i.e. geographically stable).

Exclusion

  • Subject has preexisting valve prosthesis or annuloplasty rings in the mitral, pulmonic or tricuspid position.
  • Subject requires a double or multiple valve replacement or repair of the mitral, tricuspid, or pulmonic valve.
  • Subject requiring simultaneous cardiac procedures, apart from septal myectomy and/or coronary by-pass graft (CABG).
  • Subject has active endocarditis.
  • Subject has active myocarditis
  • Subject has aneurysmal dilation or dissection of the ascending aortic wall.
  • Subject is drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
  • Subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject.
  • Subject with known hypersensitivity to nickel alloys.
  • Subject is undergoing renal dialysis for chronic renal failure or has hyperparathyroidism.
  • Subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized for ≥30 days prior to the planned valve implant surgery.
  • Subject is known to be noncompliant or is unlikely to complete the study.
  • Subject with an aortic root enlargement, where the ratio between the diameter of the STJ and the annulus diameter, assessed by TEE, is \> 1.3. Or for other anatomical reasons that not suitable for PERCEVAL S per IB.

Key Trial Info

Start Date :

January 26 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 25 2024

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT03481387

Start Date

January 26 2018

End Date

February 25 2024

Last Update

March 6 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fuwai Hospital CAMS&PUMC

Beijing, China